|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
We conclude that elevated GIP levels in obesity are likely a consequence of increased endocannabinoid levels.
|
28655715 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP is well known to contribute to HFD-induced obesity.
|
29406782 |
2018 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
Nonetheless, interrogation of the GIP/GIPR axis on cardiac function in humans will involve the systemic actions of the GIPR within the myocardium and other systems (e.g. adipose tissue, vasculature), which will influence the long-term future of GIPR modification for the treatment of obesity/T2DM.
|
31812593 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP analogues and the treatment of obesity-diabetes.
|
31756366 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity.
|
30726969 |
2019 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of GIP, which occurs in obesity, might thereby be contributing to the enhanced rate of carcinogenesis observed in obesity.
|
20433877 |
2010 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
To investigate the effects of the novel glucose-dependent insulinotropic polypeptide (GIP) analogue, ZP4165, on body weight and glycaemic control in rodents, and to investigate if ZP4165 modulates the anti-obesity and anti-hyperglycaemic effects of a glucagon-like peptide-1 (GLP-1) agonist (liraglutide).
|
28598027 |
2018 |
|
Obesity
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Therefore, elevated Pro-CT and CGRP-I levels in obesity might result from GIP-induced Pro-CT and CGRP-I release in AT and might be triggered by a high-fat diet.
|
21106708 |
2011 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Ambiguity regarding the role of glucose-dependent insulinotropic polypeptide (GIP) in obesity arises from conflicting reports asserting that both GIP receptor (GIPR) agonism and antagonism are effective strategies for inhibiting weight gain.
|
31447324 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Antagonizing the glucose-dependent insulinotropic polypeptide (GIP) receptor may open up new therapeutic modalities in the treatment of diabetes and obesity.
|
28055305 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
This review will discuss the physiological effects of GIP on fat metabolism in human adipose and other non-adipose tissues such as liver, pancreas, skeletal muscle and heart, describe where the actions of GIP may contribute to the pathophysiology of obesity, T2D and NAFLD and finally describe the therapeutic implications of GIP antagonism and agonism in these conditions.
|
31759125 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Given the established roles of glucose-dependent insulinotropic polypeptide (GIP) in promoting fat storage and bone formation, we assessed the contribution of GIP to obesity and osteopenia in ovariectomized mice with a gene encoding green fluorescent protein (GFP) inserted into the GIP locus, in which GIP was either reduced (GIP<sup>gfp/+</sup> ) or absent (GIP<sup>gfp/gfp</sup> ).
|
30451382 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Since glucose-dependent insulinotropic polypeptide (GIP) is a strong stimulator of adipogenesis and may play a role in the development of obesity, we explored whether GIP directly would stimulate OPN expression in adipose tissue and thereby induce insulin resistance.
|
23349498 |
2013 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) has been identified in multiple genome-wide association studies (GWAS) as a contributor to obesity, and GIPR knockout mice are protected against diet-induced obesity (DIO).
|
30567927 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
We hypothesized that GIP is anabolic in human subcutaneous adipose tissue (SAT) promoting triacylglycerol (TAG) deposition through reesterification of nonesterified fatty acids (NEFA), and this effect may differ according to obesity status or glucose tolerance.
|
28073779 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Lastly, we discuss how dysmetabolic conditions such as obesity and type 2 diabetes may shift the actions of GIP in an atherogenic direction, and we provide a perspective on the therapeutic potential of GIP receptor agonism and antagonism in cardiovascular diseases.
|
31689454 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent studies with a GIP receptor antagonist suitable for human studies have confirmed these concepts regarding the actions of endogenous GIP and point to potential beneficial metabolic effects of GIP receptor antagonists rather than agonist in the treatment of obesity and type 2 diabetes.
|
31838219 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
A dual incretin receptor agonist designed to co-activate GLP-1 and GIP receptors was recently shown to elicit robust improvements of glycemic control (mean haemoglobin A1c reduction of 1.94%) and massive body weight loss (mean weight loss of 11.3 kg) after 26 weeks of treatment with the highest dose (15 mg once weekly) in a clinical trial including overweight/obese patients with type 2 diabetes.
|
31443356 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, observations in transgenic GIP receptor deficient mice indicate that GIP directly links overnutrition to obesity, therein playing a crucial role in the development of obesity and related metabolic disorders.
|
14607102 |
2003 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Recent studies in rodents suggested that GIP directly links overnutrition to obesity.
|
17395281 |
2007 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
This, together with reports on GIP antagonists that may protect against obesity, has revived the interest on the GIP/GIPR axis as a potential anti-diabetic pathway.
|
31751656 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
As such, blockade of GIP receptor (GIPR) action has been proposed as a means to counter insulin resistance, and improve metabolic status in obesity and related diabetes.
|
31733230 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this review, we first summarize our traditional understanding of the physiology of GIP and GLP-1, and our current knowledge of the relationships between GIP and GLP-1 and obesity and diabetes.
|
31392745 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
A synthetic monomeric peptide triple receptor agonist, termed "Triagonist" that incorporates glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (Gcg) actions, was previously developed to improve upon metabolic and glucose regulatory benefits of single and dual receptor agonists in rodent models of diet-induced obesity and type 2 diabetes.
|
31730763 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Augmentation of glucose mediated insulin release, the incretin effect, was discovered soon after GIP was first isolated and only much later was its important role in the pathogenesis of obesity, through mechanism other than insulin secretion, appreciated.
|
31539554 |
2019 |